$175 Million is the total value of Soleus Capital Management, L.P.'s 61 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZYME | New | ZYMEWORKS INCput | $11,827,000 | – | 327,900 | +100.0% | 6.74% | – |
| AZN | New | ASTRAZENECA PLCsponsored adr | $7,204,000 | – | 136,214 | +100.0% | 4.11% | – |
| PRTA | New | PROTHENA CORP PLC | $7,056,000 | – | 674,603 | +100.0% | 4.02% | – |
| QDEL | New | QUIDEL CORP | $6,913,000 | – | 30,900 | +100.0% | 3.94% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $5,531,000 | – | 34,500 | +100.0% | 3.15% | – |
| IMMU | New | IMMUNOMEDICS INC | $4,217,000 | – | 119,000 | +100.0% | 2.40% | – |
| LLY | New | LILLY ELI & CO | $3,414,000 | – | 20,800 | +100.0% | 1.95% | – |
| NARI | New | INARI MED INC | $3,188,000 | – | 65,817 | +100.0% | 1.82% | – |
| OSUR | New | ORASURE TECHNOLOGIES INC | $2,595,000 | – | 223,200 | +100.0% | 1.48% | – |
| HUM | New | HUMANA INC | $2,559,000 | – | 6,600 | +100.0% | 1.46% | – |
| NVRO | New | NEVRO CORP | $2,246,000 | – | 18,800 | +100.0% | 1.28% | – |
| IONS | New | IONIS PHARMACEUTICALS INC | $2,146,000 | – | 36,400 | +100.0% | 1.22% | – |
| SRDX | New | SURMODICS INC | $1,901,000 | – | 43,978 | +100.0% | 1.08% | – |
| HZNP | New | HORIZON THERAPEUTICS PUB LTD | $1,645,000 | – | 29,600 | +100.0% | 0.94% | – |
| SILK | New | SILK RD MED INC | $1,160,000 | – | 27,711 | +100.0% | 0.66% | – |
| FATE | New | FATE THERAPEUTICS INC | $1,132,000 | – | 33,000 | +100.0% | 0.64% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $1,023,000 | – | 14,000 | +100.0% | 0.58% | – |
| New | GOSSAMER BIO INCnote 5.000% 6/0 | $1,001,000 | – | 1,000,000 | +100.0% | 0.57% | – | |
| VAPO | New | VAPOTHERM INC | $889,000 | – | 21,700 | +100.0% | 0.51% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $887,000 | – | 100,000 | +100.0% | 0.51% | – |
| PRVB | New | PROVENTION BIO INC | $845,000 | – | 59,900 | +100.0% | 0.48% | – |
| PODD | New | INSULET CORP | $777,000 | – | 4,000 | +100.0% | 0.44% | – |
| MASI | New | MASIMO CORP | $775,000 | – | 3,400 | +100.0% | 0.44% | – |
| LYRA | New | LYRA THERAPEUTICS INC | $687,000 | – | 60,670 | +100.0% | 0.39% | – |
| CSTL | New | CASTLE BIOSCIENCES INC | $565,000 | – | 15,000 | +100.0% | 0.32% | – |
| INSP | New | INSPIRE MED SYS INC | $488,000 | – | 5,608 | +100.0% | 0.28% | – |
| RAPT | New | RAPT THERAPEUTICS INC | $438,000 | – | 15,100 | +100.0% | 0.25% | – |
| LRMR | New | LARIMAR THERAPEUTICS INC | $400,000 | – | 31,170 | +100.0% | 0.23% | – |
| ARVN | New | ARVINAS INC | $201,000 | – | 6,000 | +100.0% | 0.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.